{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:05:17Z","timestamp":1769169917693,"version":"3.49.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00277-023-05088-7","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T04:39:44Z","timestamp":1675053584000},"page":"597-601","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Venetoclax-based combination therapy in R\/R DLBCL patients with failure of CAR-T therapy"],"prefix":"10.1007","volume":"102","author":[{"given":"Ying","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sicheng","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengya","family":"Cong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"issue":"5","key":"5088_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjh.15412","volume":"182","author":"C Gisselbrecht","year":"2018","unstructured":"Gisselbrecht C, Van Den Neste E (2018) How I manage patients with relapsed\/refractory diffuse large B cell lymphoma. Br J Haematol 182(5):633\u2013643","journal-title":"Br J Haematol"},{"issue":"3","key":"5088_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","volume":"31","author":"C Sarkozy","year":"2018","unstructured":"Sarkozy C, Sehn LH (2018) Management of relapsed\/refractory DLBCL. Best Pract Res Clin Haematol 31(3):209\u2013216","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"5088_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","volume":"34","author":"JS Abramson","year":"2020","unstructured":"Abramson JS (2020) Anti-CD19 CAR T-Cell Therapy for B-cell non-Hodgkin lymphoma. Transfus Med Rev 34(1):29\u201333","journal-title":"Transfus Med Rev"},{"issue":"11","key":"5088_CR4","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","volume":"11","author":"I Kapoor","year":"2020","unstructured":"Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A (2020) Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis 11(11):941","journal-title":"Cell Death Dis"},{"issue":"8","key":"5088_CR5","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG et al (2017) Phase I first-in-human study of venetoclax in patients ewwith relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 35(8):826\u2013833","journal-title":"J Clin Oncol"},{"issue":"5","key":"5088_CR6","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood.2020006578","volume":"137","author":"PF Franck Morschhauser","year":"2021","unstructured":"Franck Morschhauser PF (2021) A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood 137(5):600\u2013609","journal-title":"Blood"},{"issue":"14","key":"5088_CR7","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1158\/0008-5472.CAN-17-0082","volume":"77","author":"S O'Steen","year":"2017","unstructured":"O\u2019Steen S, Green DJ, Gopal AK, Orozco JJ, Kenoyer AL, Lin Y et al (2017) Venetoclax synergizes with radiotherapy for treatment of B-cell lymphomas. Cancer Res 77(14):3885\u20133893","journal-title":"Cancer Res"},{"issue":"14","key":"5088_CR8","first-page":"1632","volume":"136","author":"CT Weidong Han","year":"2020","unstructured":"Weidong Han CT, Zhang Yajing (2020) Optimized tandem CD19 CD20 CAR-engineered T cells in refractory relapsed B cell lymphoma. Blood. 136(14):1632\u201344","journal-title":"Blood."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05088-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05088-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05088-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T06:07:00Z","timestamp":1677650820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05088-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["5088"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05088-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"25 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}